An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users

被引:34
作者
Richter, A
Brandeau, ML [1 ]
Owens, DK
机构
[1] Stanford Univ, Dept Ind Engn & Engn Management, Stanford, CA 94305 USA
[2] Stanford Univ, Ctr Primary Care & Outcomes Res, Dept Med, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[4] Res Triangle Inst, Ctr Econ Res, Durham, NC USA
[5] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
关键词
HIV; AIDS; HIV-1; resource allocation; prevention; cost-benefit analysis;
D O I
10.1177/0272989X9901900207
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Millions of dollars are spent annually to prevent infection with human immunodeficiency virus (HIV) without a thorough understanding of the most effective way to allocate these resources. The authors' objective was to determine the allocation of new resources among prevention programs targeted to a population of injection drug users (IDUs) and a population of non-injection drug users (non-IDUs) that would minimize the total number of incident cases of HIV infection over a given time horizon. They developed a dynamic model of HIV transmission in IDUs and non-IDUs and estimated the relationship between prevention program expenditures and reductions in HIV transmission. They evaluated three prevention programs: HIV testing with routine counseling, HIV testing with intensive counseling, and HIV testing and counseling linked to methadone maintenance programs. They modeled a low-risk IDU population (5% HIV prevalence) and a moderate-risk IDU population (10% HIV prevalence). For different available budgets, they determined the allocation of resources among the prevention programs and populations that would minimize the number of new cases of HIV infection over a five-year period, as well as the incremental value of additional prevention funds. The study framework provides a quantitative, systematic approach to funding programs to prevent HIV infection that accounts for HIV transmission dynamics, population size, and the costs and effectiveness of the interventions in reducing HIV transmission. The approach is general and can be used to evaluate a broader group of prevention programs and risk populations. This framework thus could enable policy makers and clinicians to identify a portfolio of programs that provide, collectively, the most benefit for a given budget.
引用
收藏
页码:167 / 179
页数:13
相关论文
共 46 条
[1]  
BARNETT PG, 1998, COST SUBSTANCE ABUSE
[2]  
BENNETT A, 1996, WALL STREET J 0501, pA6
[3]  
BENNETT A, 1996, WALL STREET J 0501, pA1
[4]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[5]   PREVENTION OF HIV-INFECTION [J].
CHOI, KH ;
COATES, TJ .
AIDS, 1994, 8 (10) :1371-1389
[6]   AIDS VACCINES - ARE RESEARCHERS RACING TOWARD SUCCESS, OR CRAWLING [J].
COHEN, J .
SCIENCE, 1994, 265 (5177) :1373-1375
[7]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[8]   SCREENING FOR BREAST-CANCER [J].
EDDY, DM .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (05) :389-399
[9]   SCREENING FOR CERVICAL-CANCER [J].
EDDY, DM .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (03) :214-226
[10]   SCREENING FOR LUNG-CANCER [J].
EDDY, DM .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (03) :232-237